Butorphanol-mediated antinociception in mice: Partial agonist effects and Mu receptor involvement

H. R. Garner, Timothy F. Burke, C. David Lawhorn, JoAnne Stoner, William D. Wessinger

Research output: Contribution to journalArticle

32 Citations (Scopus)

Abstract

In the present experiments, we characterized the agonist and antagonist effects of butorphanol in mice. In the mouse radiant-heat tail-flick test, the mu agonists morphine and fentanyl and the kappa agonist U50,488H were fully effective as analgesics, whereas butorphanol was partially effective (producing 82% of maximal possible analgesic effect). Naltrexone was approximately equipotent in antagonizing the effects of morphine, fentanyl and butorphanol; in vivo apparent pA2 values for these naltrexone/agonist interactions were 7.5 (unconstrained). Naltrexone was ~10 times less potent in antagonizing the effect of U50,488H (average apparent pK(B) = 6.7). The selective mu antagonist β-funaltraxamine (0.1-1.0 mg/kg) antagonized the effects of butorphanol in a dose-dependent insurmountable manner. Pretreatment with nor-binaltorphimine (32 mg/kg), a kappa-selective antagonist, did not reliably antagonize butorphanol, and naltrindole (20 and 32 mg/kg), a delta-selective antagonist, failed to antagonize the effects of butorphanol. Low doses of butorphanol (1.0, 1.8 or 3.2 mg/kg) caused parallel, rightward shifts in the dose-effect curve for morphine and parallel leftward shifts in the dose-effect curve for U50,488H. Taken together, the results of the present study suggest that butorphanol is a partial agonist in the mouse radiant-heat tail-flick test and that activity at mu receptors accounts for the majority of its antinociceptive effects.

Original languageEnglish (US)
Pages (from-to)1253-1261
Number of pages9
JournalJournal of Pharmacology and Experimental Therapeutics
Volume282
Issue number3
StatePublished - Sep 1997
Externally publishedYes

Fingerprint

Butorphanol
mu Opioid Receptor
Naltrexone
Morphine
naltrindole
Fentanyl
Analgesics
Tail
Hot Temperature

ASJC Scopus subject areas

  • Pharmacology

Cite this

Butorphanol-mediated antinociception in mice : Partial agonist effects and Mu receptor involvement. / Garner, H. R.; Burke, Timothy F.; Lawhorn, C. David; Stoner, JoAnne; Wessinger, William D.

In: Journal of Pharmacology and Experimental Therapeutics, Vol. 282, No. 3, 09.1997, p. 1253-1261.

Research output: Contribution to journalArticle

Garner, H. R. ; Burke, Timothy F. ; Lawhorn, C. David ; Stoner, JoAnne ; Wessinger, William D. / Butorphanol-mediated antinociception in mice : Partial agonist effects and Mu receptor involvement. In: Journal of Pharmacology and Experimental Therapeutics. 1997 ; Vol. 282, No. 3. pp. 1253-1261.
@article{2fd7726f290c49009d224a89f00548c0,
title = "Butorphanol-mediated antinociception in mice: Partial agonist effects and Mu receptor involvement",
abstract = "In the present experiments, we characterized the agonist and antagonist effects of butorphanol in mice. In the mouse radiant-heat tail-flick test, the mu agonists morphine and fentanyl and the kappa agonist U50,488H were fully effective as analgesics, whereas butorphanol was partially effective (producing 82{\%} of maximal possible analgesic effect). Naltrexone was approximately equipotent in antagonizing the effects of morphine, fentanyl and butorphanol; in vivo apparent pA2 values for these naltrexone/agonist interactions were 7.5 (unconstrained). Naltrexone was ~10 times less potent in antagonizing the effect of U50,488H (average apparent pK(B) = 6.7). The selective mu antagonist β-funaltraxamine (0.1-1.0 mg/kg) antagonized the effects of butorphanol in a dose-dependent insurmountable manner. Pretreatment with nor-binaltorphimine (32 mg/kg), a kappa-selective antagonist, did not reliably antagonize butorphanol, and naltrindole (20 and 32 mg/kg), a delta-selective antagonist, failed to antagonize the effects of butorphanol. Low doses of butorphanol (1.0, 1.8 or 3.2 mg/kg) caused parallel, rightward shifts in the dose-effect curve for morphine and parallel leftward shifts in the dose-effect curve for U50,488H. Taken together, the results of the present study suggest that butorphanol is a partial agonist in the mouse radiant-heat tail-flick test and that activity at mu receptors accounts for the majority of its antinociceptive effects.",
author = "Garner, {H. R.} and Burke, {Timothy F.} and Lawhorn, {C. David} and JoAnne Stoner and Wessinger, {William D.}",
year = "1997",
month = "9",
language = "English (US)",
volume = "282",
pages = "1253--1261",
journal = "Journal of Pharmacology and Experimental Therapeutics",
issn = "0022-3565",
publisher = "American Society for Pharmacology and Experimental Therapeutics",
number = "3",

}

TY - JOUR

T1 - Butorphanol-mediated antinociception in mice

T2 - Partial agonist effects and Mu receptor involvement

AU - Garner, H. R.

AU - Burke, Timothy F.

AU - Lawhorn, C. David

AU - Stoner, JoAnne

AU - Wessinger, William D.

PY - 1997/9

Y1 - 1997/9

N2 - In the present experiments, we characterized the agonist and antagonist effects of butorphanol in mice. In the mouse radiant-heat tail-flick test, the mu agonists morphine and fentanyl and the kappa agonist U50,488H were fully effective as analgesics, whereas butorphanol was partially effective (producing 82% of maximal possible analgesic effect). Naltrexone was approximately equipotent in antagonizing the effects of morphine, fentanyl and butorphanol; in vivo apparent pA2 values for these naltrexone/agonist interactions were 7.5 (unconstrained). Naltrexone was ~10 times less potent in antagonizing the effect of U50,488H (average apparent pK(B) = 6.7). The selective mu antagonist β-funaltraxamine (0.1-1.0 mg/kg) antagonized the effects of butorphanol in a dose-dependent insurmountable manner. Pretreatment with nor-binaltorphimine (32 mg/kg), a kappa-selective antagonist, did not reliably antagonize butorphanol, and naltrindole (20 and 32 mg/kg), a delta-selective antagonist, failed to antagonize the effects of butorphanol. Low doses of butorphanol (1.0, 1.8 or 3.2 mg/kg) caused parallel, rightward shifts in the dose-effect curve for morphine and parallel leftward shifts in the dose-effect curve for U50,488H. Taken together, the results of the present study suggest that butorphanol is a partial agonist in the mouse radiant-heat tail-flick test and that activity at mu receptors accounts for the majority of its antinociceptive effects.

AB - In the present experiments, we characterized the agonist and antagonist effects of butorphanol in mice. In the mouse radiant-heat tail-flick test, the mu agonists morphine and fentanyl and the kappa agonist U50,488H were fully effective as analgesics, whereas butorphanol was partially effective (producing 82% of maximal possible analgesic effect). Naltrexone was approximately equipotent in antagonizing the effects of morphine, fentanyl and butorphanol; in vivo apparent pA2 values for these naltrexone/agonist interactions were 7.5 (unconstrained). Naltrexone was ~10 times less potent in antagonizing the effect of U50,488H (average apparent pK(B) = 6.7). The selective mu antagonist β-funaltraxamine (0.1-1.0 mg/kg) antagonized the effects of butorphanol in a dose-dependent insurmountable manner. Pretreatment with nor-binaltorphimine (32 mg/kg), a kappa-selective antagonist, did not reliably antagonize butorphanol, and naltrindole (20 and 32 mg/kg), a delta-selective antagonist, failed to antagonize the effects of butorphanol. Low doses of butorphanol (1.0, 1.8 or 3.2 mg/kg) caused parallel, rightward shifts in the dose-effect curve for morphine and parallel leftward shifts in the dose-effect curve for U50,488H. Taken together, the results of the present study suggest that butorphanol is a partial agonist in the mouse radiant-heat tail-flick test and that activity at mu receptors accounts for the majority of its antinociceptive effects.

UR - http://www.scopus.com/inward/record.url?scp=0030931722&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030931722&partnerID=8YFLogxK

M3 - Article

C2 - 9316833

AN - SCOPUS:0030931722

VL - 282

SP - 1253

EP - 1261

JO - Journal of Pharmacology and Experimental Therapeutics

JF - Journal of Pharmacology and Experimental Therapeutics

SN - 0022-3565

IS - 3

ER -